These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37524153)

  • 21. "Evolution of Drug-Coated Devices for the Treatment of Chronic Limb Threatening Ischemia".
    Creeden T; Jones DW
    Ann Vasc Surg; 2024 Oct; 107():76-83. PubMed ID: 38582201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
    Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
    JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery.
    Miura T; Miyashita Y; Soga Y; Hozawa K; Doijiri T; Ikeda U; Kuwahara K;
    Circ Cardiovasc Interv; 2018 Aug; 11(8):e006564. PubMed ID: 30354784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery.
    Wooster M; Dansey K; Shames M
    Vasc Endovascular Surg; 2016 Feb; 50(2):80-3. PubMed ID: 26912397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robustness of Longitudinal Safety and Efficacy After Paclitaxel-Based Endovascular Therapy for Treatment of Femoro-Popliteal Artery Occlusive Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    D'Oria M; Mastrorilli D; Secemsky E; Behrendt CA; Veraldi G; DeMartino R; Mani K; Budtz-Lilly J; Scali S; Saab F; Calvagna C; Mezzetto L; Ruaro B; Lepidi S
    Ann Vasc Surg; 2024 Apr; 101():164-178. PubMed ID: 38154491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease.
    Mills JL; Conte MS; Murad MH
    J Vasc Surg; 2019 Jul; 70(1):3-7. PubMed ID: 31230649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel-coated peripheral artery devices are not associated with increased mortality.
    Kumins NH; King AH; Ambani RN; Thomas JP; Bose S; Shishehbor MH; Li J; Wong VL; Harth KC; Cho JS; Kashyap VS
    J Vasc Surg; 2020 Sep; 72(3):968-976. PubMed ID: 31917036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?
    Beckman JA; White CJ
    Circulation; 2019 Oct; 140(16):1342-1351. PubMed ID: 31177820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
    Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
    J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angioscopic findings from the SHIMEJI trial (Suppression of vascular wall Healing after IMplantation of drug Eluting peripheral stent in Japanese patients with the Infra inguinal lesion: serial angioscopic observation).
    Tsukiyama Y; Shinke T; Ishihara T; Otake H; Terashita D; Kozuki A; Fukunaga M; Zen K; Horimatsu T; Fujii K; Shite J; Uematsu M; Takahara M; Iida O; Nanto S; Hirata KI
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1777-1784. PubMed ID: 31201589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No Difference in Mid-term and Long-Term Mortality After Vascular Paclitaxel Exposure.
    Björkman P; Weselius EM; Venermo M
    Ann Vasc Surg; 2021 Apr; 72():253-260. PubMed ID: 32979469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices.
    Bittl JA; He Y; Baber U; Feldman RL; von Mering GO; Kaul S
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2528-2537. PubMed ID: 31857023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Biolimus Versus Everolimus for Drug-Eluting Stents in the Percutaneous Treatment of Infra-Inguinal Arterial Disease.
    Giordano A; Ferraro P; Corcione N; Messina S; Maresca G; Coscioni E; Avellino R; Giordano G; Peruzzi M; Marullo AGM; Napolitano G; Romano MF; Biondi-Zoccai G
    Curr Vasc Pharmacol; 2017; 15(3):257-264. PubMed ID: 28117007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
    Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
    J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
    J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of the 2011 food and drug administration's circulatory system devices panel of the medical devices advisory committee meeting on the Zilver® PTX® drug-eluting peripheral stent.
    Dvir D; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2012; 13(5):281-5. PubMed ID: 22898055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.
    Bosiers M; Callaert J; Keirse K; Hendriks JMH; Peeters P; Verbist J; Maene L; Beelen R; Deloose K
    J Endovasc Ther; 2017 Jun; 24(3):311-316. PubMed ID: 28351310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
    Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Rollercoaster of Paclitaxel in the Lower Limbs and Skeletons in the Closet: An Opinion Review.
    Katsanos K; Kitrou P; Spiliopoulos S
    J Vasc Interv Radiol; 2021 Jun; 32(6):785-791. PubMed ID: 33811999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and its characteristics of repetition of reintervention after drug-eluting stent implantation for femoropopliteal lesion.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Yokoi H; Uematsu M;
    J Vasc Surg; 2016 Dec; 64(6):1691-1695.e1. PubMed ID: 27575807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.